The Latest Breaking News from Eli Lilly

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.